The company intends to use the funds to advance, broaden, and accelerate the development of its ADC pipeline, including the ADCE-T02 (Tissue Factor ADC), ADCE-D01 (uPARAP ADC), ADCE-B05 and A0401 programs.

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

BioInnovation Institute, Ole Maaløes Vej 3, Copenhagen, Capi
Copenhagen, 2200
DK

Phone

Undisclosed

Website

www.adcendo.com

Email Address

[email protected]

Overview

Adcendo ApS is a Copenhagen-based biotech company dedicated to developing highly differentiated antibody-drug conjugates (ADCs) for the treatment of underserved cancers. Antibody-drug conjugates (ADCs) represent an emerging drug modality, directing anticancer therapeutics to malignant cells overexpressing particular surface target molecules. 10+ ADCs are now in routine clinical use for cancer patients, with many more novel ADC assets currently investigated in clinical studies in solid tumors and hematologic malignancies

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Michael Pehl

Chief Operating Officer

Christoffer Nielsen

Chief Scientific Officer

Dominik Mumberg

Chief Technical Officer

Pernille Hemmingsen

Browse more venture capital transactions:

Prev: 11/25/2024: PostSig venture capital transaction
Next: 11/25/2024: Secretome Therapeutics venture capital transaction

Share this article

About Our Venture Capital Transactions Database

We do our best to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary